CFTR and cystic fibrosis: In fact, several CFTR-corrector compounds have been clinically evaluated and few have even reached the CF patients in combination with CFTR-potentiator drugs Orkambi®, Symdeko® (Birault et al., 2013; Wainwright et al., 2015; Mayer, 2016), although their present costs are humongous (Mayer, 2016; Bulloch et al., 2017).